B. Riley Forecasts biote’s Q3 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD) – B. Riley issued their Q3 2025 EPS estimates for biote in a report released on Thursday, March 13th. B. Riley analyst J. Van. Sinderen forecasts that the company will post earnings of $0.10 per share for the quarter. The consensus estimate for biote’s current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote’s Q4 2025 earnings at $0.10 EPS.

Separately, Craig Hallum reduced their price objective on shares of biote from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday.

biote Price Performance

NASDAQ:BTMD opened at $3.76 on Friday. The firm has a 50-day moving average of $4.96 and a 200-day moving average of $5.55. The company has a market cap of $204.31 million, a PE ratio of 14.46 and a beta of 1.07. biote has a one year low of $3.04 and a one year high of $8.44.

Institutional Trading of biote

A number of institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP lifted its stake in shares of biote by 0.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 681,524 shares of the company’s stock valued at $4,211,000 after buying an additional 3,065 shares in the last quarter. Jane Street Group LLC lifted its stake in biote by 24.7% in the 3rd quarter. Jane Street Group LLC now owns 16,873 shares of the company’s stock worth $94,000 after purchasing an additional 3,342 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in biote by 10.2% in the 4th quarter. Ameriprise Financial Inc. now owns 36,214 shares of the company’s stock worth $224,000 after purchasing an additional 3,351 shares in the last quarter. Rhumbline Advisers lifted its stake in biote by 11.6% in the 4th quarter. Rhumbline Advisers now owns 37,688 shares of the company’s stock worth $233,000 after purchasing an additional 3,920 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in biote by 49.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,742 shares of the company’s stock worth $79,000 after purchasing an additional 4,243 shares in the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.